Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2019.1618268
Abstract: The long-term management of obesity is challenging for patients and health care providers. In addition to lifestyle interventions, there are several pharmacotherapies and bariatric surgical options available. Of the five prescription-only pharmacotherapies currently available on… read more here.
Keywords: naltrexone bupropion; drug safety; bupropion; obesity ... See more keywords
Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review
Sign Up to like & getrecommendations! Published in 2022 at "Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy"
DOI: 10.2147/dmso.s381652
Abstract: Abstract Naltrexone/Bupropion extended release (ER; Contrave) is an extended-release, fixed-dose combination medication of naltrexone (8 mg) and bupropion (90 mg) for patients with obesity or overweight with at least one weight-related comorbidity. Obese and overweight… read more here.
Keywords: bupropion naltrexone; naltrexone bupropion; mace; bupropion bupropion ... See more keywords